BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chyuan IT, Hsu PN. Tumor necrosis factor: The key to hepatitis B viral clearance. Cell Mol Immunol 2018;15:731-3. [PMID: 29375133 DOI: 10.1038/cmi.2017.139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Lu C, Fu W, Zhou R, Hu W. Network pharmacology-based study on the mechanism of Yiganling capsule in hepatitis B treatment. BMC Complement Med Ther 2020;20:37. [PMID: 32024508 DOI: 10.1186/s12906-020-2815-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Sun H, Sun C. The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy. Front Immunol 2019;10:2354. [DOI: 10.3389/fimmu.2019.02354] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
3 Wu T, Li F, Chen Y, Wei H, Tian Z, Sun C, Sun R. CD4+ T Cells Play a Critical Role in Microbiota-Maintained Anti-HBV Immunity in a Mouse Model. Front Immunol. 2019;10:927. [PMID: 31114580 DOI: 10.3389/fimmu.2019.00927] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Patel S, Kumthekar A. Psoriatic Arthritis: The Influence of Co-morbidities on Drug Choice. Rheumatol Ther 2021. [PMID: 34797530 DOI: 10.1007/s40744-021-00397-7] [Reference Citation Analysis]
5 Huang W, Du L, Tang H. Hepatitis B virus reactivation: overview and management. Future Virology 2021;16:821-35. [DOI: 10.2217/fvl-2021-0275] [Reference Citation Analysis]
6 Han Q, Hou Z, Yin C, Zhang C, Zhang J. 5'-triphosphate siRNA targeting HBx elicits a potent anti-HBV immune response in pAAV-HBV transfected mice. Antiviral Res. 2019;161:36-45. [PMID: 30448255 DOI: 10.1016/j.antiviral.2018.11.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
7 Wu Y, Wang J, Zheng X, Chen Y, Huang M, Huang Q, Xiao W, Wei H, Tian Z, Sun R, Sun C. Establishment and Preclinical Therapy of Patient-derived Hepatocellular Carcinoma Xenograft Model. Immunol Lett 2020;223:33-43. [PMID: 32335145 DOI: 10.1016/j.imlet.2020.04.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Zheng M, Tian Z. Liver-Mediated Adaptive Immune Tolerance. Front Immunol 2019;10:2525. [PMID: 31787967 DOI: 10.3389/fimmu.2019.02525] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 13.0] [Reference Citation Analysis]